Terms: = Endocrine gland cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Treatment
966 results:
1. Single-cell transcriptome analysis reveals subtype-specific clonal evolution and microenvironmental changes in liver metastasis of pancreatic adenocarcinoma and their clinical implications.
Park JK; Jeong HO; Kim H; Choi JH; Lee EM; Kim S; Jang J; Choi DW; Lee SH; Kim KM; Jang KT; Lee KH; Lee KT; Lee MW; Lee JK; Lee S
Mol Cancer; 2024 May; 23(1):87. PubMed ID: 38702773
[TBL] [Abstract] [Full Text] [Related]
2. pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model.
Dutta D; Ray P; De A; Ghosh A; Hazra RS; Ghosh P; Banerjee S; Diaz FJ; Upadhyay SP; Quadir M; Banerjee SK
PLoS One; 2024; 19(4):e0297749. PubMed ID: 38687749
[TBL] [Abstract] [Full Text] [Related]
3. Targeting kras in pancreatic cancer.
Stickler S; Rath B; Hamilton G
Oncol Res; 2024; 32(5):799-805. PubMed ID: 38686056
[TBL] [Abstract] [Full Text] [Related]
4. A pancreatic cancer organoid-in-matrix platform shows distinct sensitivities to T cell killing.
Lahusen A; Cai J; Schirmbeck R; Wellstein A; Kleger A; Seufferlein T; Eiseler T; Lin YN
Sci Rep; 2024 Apr; 14(1):9377. PubMed ID: 38654067
[TBL] [Abstract] [Full Text] [Related]
5. Disruption of the pro-oncogenic c-RAF-PDE8A complex represents a differentiated approach to treating kras-c-RAF dependent PDAC.
Cooke SF; Wright TA; Sin YY; Ling J; Kyurkchieva E; Phanthaphol N; Mcskimming T; Herbert K; Rebus S; Biankin AV; Chang DK; Baillie GS; Blair CM
Sci Rep; 2024 Apr; 14(1):8998. PubMed ID: 38637546
[TBL] [Abstract] [Full Text] [Related]
6. Genetic Signature of Human Pancreatic cancer and Personalized Targeting.
Reshkin SJ; Cardone RA; Koltai T
Cells; 2024 Mar; 13(7):. PubMed ID: 38607041
[TBL] [Abstract] [Full Text] [Related]
7. Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.
Kim YN; Chung YS; Park E; Lee ST; Lee JY
Sci Rep; 2024 Apr; 14(1):7992. PubMed ID: 38580676
[TBL] [Abstract] [Full Text] [Related]
8. Advances in Systemic Therapy in Pancreatic cancer.
Yu KH
Hematol Oncol Clin North Am; 2024 Jun; 38(3):617-627. PubMed ID: 38575456
[TBL] [Abstract] [Full Text] [Related]
9. Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection.
Brozos-Vázquez E; Toledano-Fonseca M; Costa-Fraga N; García-Ortiz MV; Díaz-Lagares Á; Rodríguez-Ariza A; Aranda E; López-López R
Cancer Treat Rev; 2024 Apr; 125():102719. PubMed ID: 38490088
[TBL] [Abstract] [Full Text] [Related]
10. First-in-Class Humanized Antibody against Alternatively Spliced Tissue Factor Augments Anti-Metastatic Efficacy of Chemotherapy in a Preclinical Model of Pancreatic Ductal Adenocarcinoma.
Lewis CS; Backman C; Ahsan S; Cliff A; Hariharan A; Yeh JJ; Zhang X; Xie C; Sohal DPS; Bogdanov VY
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473827
[TBL] [Abstract] [Full Text] [Related]
11. PRMT1 promotes pancreatic cancer development and resistance to chemotherapy.
Ku B; Eisenbarth D; Baek S; Jeong TK; Kang JG; Hwang D; Noh MG; Choi C; Choi S; Seol T; Kim H; Kim YH; Woo SM; Kong SY; Lim DS
Cell Rep Med; 2024 Mar; 5(3):101461. PubMed ID: 38460517
[TBL] [Abstract] [Full Text] [Related]
12. Twelve-month progression-free survival with sotorasib and panitumumab in kras G12C mutant metastatic colorectal cancer.
Kavgaci G; Dizdar O; Yalcin S
Anticancer Drugs; 2024 Jun; 35(5):459-461. PubMed ID: 38451823
[TBL] [Abstract] [Full Text] [Related]
13. Glycolysis-non-canonical glutamine dual-metabolism regulation nanodrug enhanced the phototherapy effect for pancreatic ductal adenocarcinoma treatment.
Qiao J; Liu S; Huang Y; Zhu X; Xue C; Wang Y; Xiong H; Yao J
J Colloid Interface Sci; 2024 Jul; 665():477-490. PubMed ID: 38429120
[TBL] [Abstract] [Full Text] [Related]
14. Stress granules-membraneless organelles as therapeutic targets in pancreatic cancer.
Schneider C; Schneider G
EMBO Mol Med; 2024 Mar; 16(3):429-431. PubMed ID: 38413839
[TBL] [Abstract] [Full Text] [Related]
15. Concurrent inhibition of pBADS99 synergistically improves MEK inhibitor efficacy in kras
Tan YQ; Sun B; Zhang X; Zhang S; Guo H; Basappa B; Zhu T; Sethi G; Lobie PE; Pandey V
Cell Death Dis; 2024 Feb; 15(2):173. PubMed ID: 38409090
[TBL] [Abstract] [Full Text] [Related]
16. Cannabigerol Induces Autophagic Cell Death by Inhibiting EGFR-RAS Pathways in Human Pancreatic Ductal Adenocarcinoma Cell Lines.
Zeppa L; Aguzzi C; Morelli MB; Marinelli O; Giangrossi M; Luongo M; Amantini C; Santoni G; Nabissi M
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396679
[TBL] [Abstract] [Full Text] [Related]
17. Complexity of the Genetic Background of Oncogenesis in Ovarian cancer-Genetic Instability and Clinical Implications.
Murawski M; Jagodziński A; Bielawska-Pohl A; Klimczak A
Cells; 2024 Feb; 13(4):. PubMed ID: 38391958
[TBL] [Abstract] [Full Text] [Related]
18. Application of plasma circulating kras mutations as a predictive biomarker for targeted treatment of pancreatic cancer.
Lee MR; Woo SM; Kim MK; Han SS; Park SJ; Lee WJ; Lee DE; Choi SI; Choi W; Yoon KA; Chun JW; Kim YH; Kong SY
Cancer Sci; 2024 Apr; 115(4):1283-1295. PubMed ID: 38348576
[TBL] [Abstract] [Full Text] [Related]
19. Genome-wide quantification of copy-number aberration impact on gene expression in ovarian high-grade serous carcinoma.
Jamalzadeh S; Dai J; Lavikka K; Li Y; Jiang J; Huhtinen K; Virtanen A; Oikkonen J; Hietanen S; Hynninen J; Vähärautio A; Häkkinen A; Hautaniemi S
BMC Cancer; 2024 Feb; 24(1):173. PubMed ID: 38317080
[TBL] [Abstract] [Full Text] [Related]
20. Droplet digital polymerase chain reaction detection of kras mutations in pancreatic FNA samples: Technical and practical aspects for routine clinical implementation.
Mansour Y; Boubaddi M; Odion T; Marty M; Belleannée G; Berger A; Subtil C; Laurent C; Dabernat S; Amintas S
Cancer Cytopathol; 2024 May; 132(5):274-284. PubMed ID: 38308613
[TBL] [Abstract] [Full Text] [Related]
[Next]